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Abstract
Reparative macrophages play an important role in cardiac repair post-myocardial infarction (MI). Bone marrow mononu-
clear cells (BM-MNCs) have been investigated as a donor for cell therapy but with limited clinical success. These cells, 
however, may be utilized as a source for reparative macrophages. This translational study aimed to establish a robust in vitro 
protocol to produce functional reparative macrophages from BM-MNCs and to establish pre-clinical evidence of the efficacy 
of reparative macrophage transplantation for the treatment of MI. Mouse BM-MNCs were treated with M-CSF plus IL-4, 
IL-10, TGF-β1 or combinations of these in vitro. The concomitant administration of M-CSF and IL-4 produced the highest 
rate and largest number of  CD11b+F4/80+CD206+ reparative macrophages. Expression and secretion of tissue repair-related 
factors including IGF-1, TGF-β1, VEGF and IL1-ra were remarkably enhanced in reparative macrophages compared to BM-
MNCs. These cells were transplanted in a mouse MI model, resulting in evident improvement in cardiac function recovery, 
compared to BM-MNC transplantation. Histological studies showed that reparative macrophage transplantation enhanced 
myocardial tissue repair including augmented microvascular formation, reduced cardiomyocyte hypertrophy and attenuated 
interstitial fibrosis. Moreover, survival of reparative macrophages in the heart post-transplantation was increased compared 
to BM-MNCs. Reparative macrophage transplantation also increased host-derived reparative macrophages in part through 
TGF-β secretion. In conclusion, concomitant M-CSF + IL-4 treatment effectively produced reparative macrophages from 
BM-MNCs in vitro. Transplantation of produced reparative macrophage achieved a superior therapeutic efficacy, compared 
to BM-MNC transplantation, through the enhanced quantity and quality of donor cell engraftment. Further development of 
this advanced cell-based therapy is warranted.
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Introduction
Recent research has revealed that there are distinct subpop-
ulations of macrophages in the heart, which contribute to 
the development of and recovery from myocardial damage 
post-MI in different ways [11, 21, 26]. Immediately after 
MI, there is a fierce inflammatory response mainly governed 
by infiltrating neutrophils, pro-inflammatory monocytes and 
M1-like macrophages [14]. The main aim of this response 
is to remove necrotic cell debris from the MI zone [14]. As 
such, in the first 3–4 days post-MI, the majority of mac-
rophages in the heart exhibit pro-inflammatory M1-like phe-
notype, while this is followed by a quick increase of M2-like 
macrophages by days 5–7 [37]. M2-like macrophages are 
capable of secreting anti-inflammatory cytokines (e.g., IL-
1ra, IL-10, TGF-β families), which contribute towards the 
resolution of inflammation in combination with pro-resolv-
ing lipid mediators [6]. M2-like macrophages also enhance 
formation of supportive connective tissues by activating 
fibroblasts through secretion of pro-fibrotic cytokines and 
by affecting the balance between matrix metalloproteinase 
(MMP) and tissue inhibitor of metalloproteinase (TIMPs) 
[29, 31, 32, 40]. Due to the inadequate regenerative ability of 
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the heart, this process is crucial to prevent rupture or exces-
sive dilatation of the fragile, infarcted ventricular walls. 
In addition, M2-like macrophages are involved in various 
stages of neovascular formation [28]. These data strongly 
suggest that further augmentation of M2-like macrophages 
will result in enhanced myocardial repair and improve prog-
nosis post-MI.
Cell transplantation has recently attracted attention as a 
new therapeutic option for MI [1]. The ease of procurement 
of a large number of autologous cells, which include multi-
ple types of stem/progenitor cells, has made bone marrow-
derived mononuclear cells (BM-MNCs) an attractive target 
for investigation as a donor cell source. BM-MNCs have 
an ability for cardiac repair post-MI through their repara-
tive secretome [13]. However, therapeutic efficacy of this 
approach in clinical trials has been inconsistent. Recent sys-
tematic reviews and meta-analyses provided evidence that 
the clinical benefit of this therapy is not as substantial as 
expected [4, 17]. The ongoing phase III clinical trial (BAMI) 
may conclude the efficacy of BM-MNC therapy [22].
Notably, BM-MNCs are a natural source of M2-like 
reparative macrophages. It is also possible to induce dif-
ferentiation/polarization of BM-MNCs to M2-like mac-
rophages in vitro using cytokines [2, 5, 16, 20, 33, 39]. 
Reparative macrophages are known to have the ability to 
secrete a powerful tissue-repairing secretome [41]. In addi-
tion, unlike BM-MNCs, which are foreign to the heart tis-
sue, reparative macrophages are cells that naturally settle in 
the damaged heart, thereby possibly exhibiting improved 
survival in the heart. The innate ability of macrophages to 
migrate and settle into the damaged tissue may also help 
effective functional engraftment of transplanted cells in the 
damaged heart, compared to BM-MNCs [21]. We, therefore, 
hypothesize that directed differentiation of donor BM-MNCs 
to a reparative macrophage phenotype prior to transplanta-
tion would augment the efficacy of BM-MNC transplanta-
tion for the treatment of MI.
This research aimed to establish an effective, clinically 
applicable cytokine combination for obtaining BM-MNC-
derived macrophages having tissue-repairing properties 
and furthermore investigated how transplantation of these 
reparative macrophages improved myocardial tissue repair 
and cardiac function in a mouse MI model.
Materials and methods
The authors declare that all data which support the find-
ings of this study are available within the article and its 
online supplementary files. Further information regarding 
this study is available from the corresponding author upon 
reasonable request.
Animals
All animal studies were performed with the approval of the 
institutional ethics committee at Queen Mary University 
of London and the Home Office, UK. The investigation 
conforms to the Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Ani-
mals (US National Institutes of Health Publication, 1996). 
Male C57BL/6 mice, 8–10 weeks old (Charles River) were 
used in all in vitro experiments and for the generation of 
donor cells. The animals were culled by  CO2 euthanasia 
immediately before the start of the bone marrow isolation 
procedure. For the in vivo experiments, the MI induction 
procedure was performed on 12-week-old female C57BL/6 
mice (Charles River).
Bone marrow extraction and BM‑MNC isolation
The mouse bone marrow was harvested by flushing the 
hind limb tibia and femur with complete DMEM medium 
(DMEM containing 10% FBS, 1%PS; Gibco). The cell 
suspension was passed through a 70-µm cell strainer and 
was centrifuged for 5 min at 400g. The resulting cell pellet 
was washed twice with phosphate buffered saline (PBS) 
and then resuspended in 5 ml cold 1× red blood cell lysis 
buffer (BioLegend), shaking gently occasionally. The reac-
tion was stopped by adding 20-ml PBS and the cells were 
pelleted (5 min at 350g). Cells were resuspended in PBS, 
loaded onto Histopaque©-1077 (Sigma-Aldrich) and cen-
trifuged for 30 min at 400g without brake. The interphase 
(containing BM-MNC) was carefully collected, washed 
once with PBS and twice with medium according to the 
manufacturer’s instructions. The cells were then resus-
pended and counted.
M2‑like macrophage generation protocol
Freshly isolated BM-MNCs were seeded onto Nunc© Cell 
Culture Treated Flasks with Filter Caps (ThermoFisher) at a 
concentration of 3.6 × 104 cells/cm2. The cells were treated 
by supplementing complete DMEM with M-CSF (20 ng/ml; 
Peprotech) and either IL-4, IL-10, TGF-β1 (20 ng/ml; Pepro-
tech) or specific combinations of them. These cytokines were 
chosen based on the fact that they have been extensively 
studied and their efficacy for M2-macrophage polarisation 
was well characterised in previous publications [2, 5, 16, 20, 
33, 39]. Specifically, the following treatments were analyzed: 
M-CSF + IL-4; M-CSF + IL-10; M-CSF + IL-4 + IL-10; 
M-CSF + IL-4 + TGF-β1; M-CSF + IL-4 + IL-10 + TGF-β1. 
Freshly isolated BM–MNC (untreated) and M0 unpolarized 
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macrophages (M-CSF only treated) were used as controls. 
The medium was changed at day 4 with fresh cytokines.
Alternatively, M2-like macrophages were produced 
using a sequential treatment protocol involving the initial 
treatment of BM-MNC with M-CSF only (20 ng/ml) for 
5 days, followed by treatment with IL-4 only (20 ng/ml) for 
an additional day (6 day protocol). M1-like macrophages 
were generated by treating BM-MNC with M-CSF (20 ng/
ml) for 5 days and after that by IFN-γ (20 ng/ml) and LPS 
(50 ng/ml) for another 2 days. M-CSF was withdrawn from 
the culture medium in the M1 polarization step.
Flow cytometry
Cells were collected from the culture flasks by scraping, 
counted and resuspended in PBS to yield 4–5 × 105 cells/
tube (minimum 2 × 105). Cells were pelleted (centrifuged 
at 300g for 5 min) and resuspended in 100-µl flow cytom-
etry buffer (5% FBS, 0.002%  NaN3 in PBS). The cells were 
blocked with anti-mouse CD16/32 antibody (IgG2a, 93, 
monoclonal, rat; 1:100) for 30 min on ice, and then incu-
bated with conjugated antibodies (Table S1) for 30 min on 
ice. Samples stained with suitable IgG controls (Table S1) 
served as negative controls and were also used for gating 
purposes. Finally, the cells were washed once with buffer, 
resuspended in 500-µl buffer, and further stained with DAPI 
(2 ng/µl) as a viability marker and transferred to polysty-
rene flow cytometry tubes. Expression of macrophage sur-
face markers was assessed using the BD LSRFortessa© cell 
analyzer and the acquired data were further processed with 
the FlowJo software (v.10). In each sample, 10,000 events in 
the final gate were recorded. Appropriate compensation was 
performed using UltraComp© eBeads (Invitrogen) before 
each experiment. Cellular debris, doublets and dead cells 
were excluded during the processing step (Figure S1).
RNA extraction from cultured cells
Macrophages and BM-MNCs (1.5 × 106 cells/sample) were 
collected from culture by scraping. RNA was extracted 
using TRIzol© reagent (Invitrogen) according to the manu-
facturer’s instructions. The RNase-Free DNase set (Qiagen) 
was used to digest contaminating DNA according to the 
manufacturer’s instructions. The purified RNA was either 
used immediately for downstream applications or stored at 
− 20 °C for short-term use.
cDNA reverse transcription
Reverse transcription of RNA samples was carried out 
using the Applied Biosystems High-Capacity cDNA 
Reverse Transcription Kit© according to manufacturer’s 
instructions. Briefly, 2× reverse transcription (RT) master 
mix was prepared using the reagents provided in the kit. 
Then, 1 µg/ml RNA in a 10-µl volume was added to 10 µl 
of 2× Master Mix or to Master Mix without the reverse 
transcriptase (no RT control). In addition, a no-template 
control was prepared (master mix with no sample added). 
All these steps were performed on ice. All the resulting 
samples were briefly centrifuged and loaded into a thermal 
cycler.
Real‑time qPCR
PCR primers (IDT) for the following genes: Arg1, Fizz1, 
Ym1, Tnfa, Il-10, Igf1, Tgfb1, Vegfa, IL-1ra, Mmp9, Ptges2, 
Timp1 and Spp1 were used (Table S2). The analysis was 
carried out on freshly isolated BM-MNC (control), M2(IL-
4) macrophages and inflammation-subjected M2(IL-4) 
macrophages. GAPDH was used as an internal control for 
normalizing relative expression levels between samples. 
Real-time quantitative PCR was performed from reverse 
transcribed cDNA samples using the Powerup SYBR Green 
Master Mix. Briefly, 5 ng of cDNA was added to a Micro-
Amp© Optical 96-well reaction plate (Applied Biosystems) 
with 1× Powerup SYBR Green© Master Mix, 2.4 μl of 
nuclease free water and forward and reverse primers (both 
at 10 µM). Thermal cycling and fluorescent monitoring was 
performed using the StepOne© Detection System (Applied 
Biosystems). For each target gene, besides the biological 
replicates, three technical replicates were performed. Nega-
tive controls using RNA as template were also included in 
all runs to test for the possible genomic DNA contamination 
of the samples.
Cell yield calculations
The number of cells was recorded at the start and the end 
of each protocol by trypan blue dye (0.4%, ThermoFisher 
Scientific) staining and automated cell counting (Countess© 
II Automated Cell Counter, Thermo Fisher). The yield was 
calculated using the following formula: Yield (%) = number 
of viable harvested cells/starting viable cell number × 100.
Inflammatory stimuli treatment of M2(IL‑4) 
macrophages
M2-like macrophages (M-CSF + IL-4 polarized, at day 6 of 
the protocol) were subjected to inflammatory stimuli (IFN-γ-
20 ng/ml and LPS 50 ng/ml; Peprotech) for 6 h in complete 
medium [24]. Subsequently, the inflammatory stimuli were 
withdrawn and the macrophages were used in downstream 
applications: qPCR analysis or ELISA.
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Conditioned medium experiments
M2(IL-4) macrophages or freshly isolated BM-MNCs 
were incubated for 24 h with serum-free DMEM. After the 
culture period, the medium was collected and centrifuged 
at 300g for 5 min and the supernatant was used in fur-
ther applications as M2(IL-4) macrophage or BM-MNC-
conditioned medium. M0 (unpolarised) macrophages 
were obtained by treating freshly isolated BM-MNCs with 
M-CSF (20 ng/ml) for 5 days. These cells were then incu-
bated for 24 h with conditioned medium from BM-MNC 
or M2(IL-4) macrophages. In addition, either 50 μg/ml 
TGF-β pan-specific neutralizing antibody (R&D Systems) 
[19] or equal amount of rabbit polyclonal antibody was 
applied to the M2(IL-4)-conditioned medium. M-CSF 
(20 ng/ml) was maintained for the co-culture duration.
Enzyme linked immunosorbent assay (ELISA)
ELISA was performed on conditioned medium from 
freshly isolated BM-MNC and IL-4-polarized M2 mac-
rophages. Regardless of the condition, the cells received 
fresh medium without any cytokines and were maintained 
in culture for 24 h. The medium was then collected and 
analyzed using ELISA kits (Quantikine© ELISA kits for 
TGF-β1, VEGF, IL-1ra and IGF-1, R&D Systems) accord-
ing to the manufacturer’s instructions.
The IGF-1 samples required a 1:2 dilution, while the 
TGF-β1 samples required activation with 1 N HCl and 
1.2 N NaOH/0.5 M HEPES in  dH2O before the start of 
the protocol.
PKH26 staining
Both BM-MNC and M2(IL-4) macrophages were stained 
with PKH26 ethanoic dye solution (1 mM, Sigma Aldrich) 
immediately prior to transplantation into animals, accord-
ing to the manufacturer’s instructions. The PKH26 dye 
was diluted (to 4 μM) in diluent C and 25 μl of this solu-
tion was used per 5 × 105 harvested cells (1 × 107 cells/ml). 
The diluted dye was immediately added to an adequate 
equal volume of diluent C that was already containing the 
cell suspension and left to incubate for 4 min. Homog-
enous staining was achieved by vigorous mixing. Finally, 
an equal volume of 100% FBS was added to the solution 
to stop the staining reaction. The cells were then washed 
three times in 10-ml complete DMEM medium. Successful 
staining was assessed immediately after staining by bright 
field microscopy using a BZ800 Keyence Microscope.
Myocardial infarction induction and cell 
transplantation
As previously described [30], MI was induced in 12-week-
old female C57BL/6 mice by ligation of the left coronary 
artery using an 8–0 polypropylene suture through left thora-
cotomy under 2.0% isoflurane anesthesia and mechanical 
ventilation (intubation aided by tracheotomy). The success 
of the procedure was determined by the positive observa-
tion of myocardial discoloration and changes in the left 
ventricular wall mechanics. Immediately after ligation, two 
injections of 10-μl PBS each containing male, PKH26 pre-
labelled cells (5 × 105 BM-MNC or 5 × 105 M2-IL-4 mac-
rophages in total) or PBS alone were injected intramyocardi-
ally in the infarct border zone. The chest and skin were then 
closed using a 5–0 VicrylPlus© Antibacterial suture. The 
animals were placed on a heating pad and carefully observed 
for the next 2–3 h until they achieved full locomotor behav-
ior. Analgesics (0.5 mg/kg—subcutaneous injection) were 
administered before the surgery and then twice a day for a 
duration of 3 days after surgery.
Echocardiography
Transthoracic echocardiography was performed 28 days 
after treatment using a Vevo-3100 Preclinical Imaging Plat-
form (VisualSonics© Fuji Film) with a 70-MHz ultrahigh-
frequency transducer under 2.0% isoflurane inhalation [30]. 
Briefly, the mice were abdominally shaved, anesthetized and 
placed on a heat pad containing electrocardiography elec-
trodes and capable of tracing heart rate, respiratory rate and 
internal temperature. Systolic (LVDs) and diastolic (LVDd) 
left ventricular dimensions as well as fractional shortening 
were measured from the short axis M-mode images using 
the VevoLab (version 3.1.0) software. Data were collected 
from three different measurements made on three different 
echocardiographic images per mouse in a blinded manner.
Quantitative assessment of donor cell presence 
and RNA extraction from left ventricular tissue
To quantify the presence of engrafted male, mouse BM-
MNC and M2(IL-4) macrophages in the female mouse 
heart, the presence of the Y chromosome-specific Sry gene 
was quantitatively assessed by real-time PCR as previously 
described [12]. The left ventricular myocardium was col-
lected 28 days after treatment (with removal of atriums 
and right ventricular free walls) and preserved in RNAlater 
(Ambion). The tissue was homogenised using the Percellys 
Lysing kit containing ceramic beads. The resulting lysate 
was further disrupted using QIAshredder (Qiagen). Genomic 
DNA was extracted using the AllPrep DNA/RNA Mini Kit 
according to the manufacturer’s instructions. To generate 
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a standard curve, left ventricular myocardium from female 
mice was mixed with known amounts of male mouse M2(IL-
4) macrophages or BM-MNCs and subsequently processed 
for Sry analysis. The signal in each LV sample was normal-
ized to the amount of DNA by measuring the autosomal 
single-copy gene GAPDH as an internal standard and read 
against the standard curve.
RNA was also extracted from the same heart samples 
using the AllPrep DNA/RNA Mini Kit according to the 
manufacturer’s instructions. Genomic DNA digestion was 
performed using the RNase-Free DNase set (Qiagen) accord-
ing to the manufacturer’s instructions. The RNA was imme-
diately used in downstream applications or stored at − 20 °C 
until required.
Cryosectioning
Mice were culled by  CO2 inhalation and their hearts were 
immediately excised, rinsed in PBS, frozen in optimal cut-
ting temperature (OCT) compound and stored at − 80 °C. 
Hearts were serially cryosectioned at a thickness of 6 μm 
using a Bright cryostat. The cryosections were then trans-
ferred on Polysine Adhesion Slides (Thermo Scientific) and 
maintained at − 80 °C until required for staining.
Immunohistochemistry and histological analysis
The cryosections were thawed and fixed for 30 min with 
4% paraformaldehyde, washed three times in PBS (5 min 
each), permeabilized in Triton X-100 (0.1%) for 10 min 
and washed again three times in PBS. This was followed by 
blocking with 5% BSA/PBS solution for 1 h. Subsequently, 
the cells were incubated with primary antibodies (Table S3) 
overnight at 4 °C, washed three times in PBS and afterwards 
incubated with the secondary antibodies (Table S3) for 1 h 
at room temperature. Conjugated WGA-FITC was added 
together with the secondary AF647 antibody (for 1 h). All 
antibodies were diluted to the working concentration in 5% 
BSA/PBS solution. Sections were further stained with DAPI 
(1 ng/µl). Finally, the sections were washed again three times 
in PBS and the slides were mounted with Dako Mounting 
Medium (Agilent).
Images were captured using a fluorescence microscope 
(BZ8000; Keyence, Milton Keynes, UK; 20× or 40× objec-
tives) and analyzed using ImageJ software. The quantitative 
assessments of  CD206+ M2-like macrophages and blood 
capillary density (IB4 staining) were conducted in five ran-
domly selected fields per each area of the heart (infarct, bor-
der, remote). To evaluate cardiomyocyte size, the cross-sec-
tional area of appropriately detected α-sarcomeric  actinin+ 
cardiomyocytes (transversely cut, exhibiting central nuclei) 
was measured for 40 cardiomyocytes from 5 fields of view 
per area (border and remote). PKH26 and CD206 co-staining 
was assessed from four fields of view per area.
Picrosirius red staining
Frozen heart sections were fixed in 4% paraformaldehyde, 
incubated in 0.1% Picrosirius red solution for 60 min and 
then in 0.5% of acetic acid solution for 3 min. Sections were 
washed three times for 5 min between each of these steps. 
The samples were dehydrated through immersion in increas-
ing concentrations of ethanol (70% and 100%) and xylene 
(20 s each immersion). Finally, the sections were mounted 
using DPX mounting medium (VWR International). The 
wall thickness was measured at five independent regions of 
the infarct area. The quantity of the collagen fraction was 
calculated from five fields (20× magnification) of each area 
per heart using the ImageJ software [30]. In addition, infarct 
size was measured as the ratio of both epicardial and endo-
cardial scar lengths relative to total epicardial and endocar-
dial circumference as previously described [35].
Statistical analysis
The statistical analysis was conducted using the GraphPad 
Prism (v.5.04) software. All data sets were statistically ana-
lyzed by either performing the one-way ANOVA analysis 
followed by Bonferroni’s Multiple Comparisons Test (three 
or more sets of data) or Student’s t test (two sets of data). 
All data sets are presented as mean ± SEM. The significance 
threshold was set at p < 0.05.
Results
M‑CSF + IL‑4 treatment was effective to produce 
M2‑like macrophages
To optimize the in vitro treatment to produce M2-like mac-
rophages, mouse BM-MNCs were treated with M-CSF and 
one or combinations of known M2-like polarizing cytokines, 
including IL-4, IL-10 and TGF-β1 for 7 days. Approxi-
mately, 70% of freshly isolated BM-MNCs were positive 
for CD11b, a monocyte precursor marker (Figs. 1a, S2). 
However, triple positive cells for CD11b, F4/80 and CD206, 
which were defined as M2-like macrophages [31], were 
hardly found in BM-MNCs (Fig. 1a, b). In contrast, after 
7 days of in vitro culture with M-CSF + IL-4, over 99% of 
the cells were positive for CD11b (Figure S2) and approxi-
mately 90% of these cells were also positive for F4/80 and 
CD206 (Fig. 1b, c). Culture with M-CSF + IL-10 achieved 
only 60% triple positivity, while M-CSF + TGF-β1 did not 
allow BM-MNCs to survive for 7 days. Addition of TGF-
β1 and/or IL-10 to the M-CSF + IL-4 treatment reduced 
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production of  CD11b+ F4/80+CD206+ M2-like macrophages 
(Fig. 1b, c). Furthermore, the absolute number of produced 
 CD11b+F4/80+CD206+ M2-like macrophages was increased 
by M-CSF + IL-4 treatment compared to other treatments 
(Fig. 1d). The M-CSF + IL-4 treatment increased by approx-
imately 1.7-fold the number of  CD11b+F4/80+CD206+ 
M2-like macrophages as compared to the originally plated 
BM-MNCs.
As M-CSF + IL-4 treatment was the most effective in 
producing  CD11b+F4/80+CD206+ M2-like macrophages, 
we aimed to determine its minimal required culture period. 
Flow cytometry analysis clarified that the percentage of 
 CD11b+F4/80+CD206+ cells started increasing by day 4 
and plateaued from day 6 at around 90% (Fig. 2a, b). In 
addition, these cells started to show specific M2-like mor-
phologic characteristics [23] as early as day 4 but with larger 
numbers of cells exhibiting the spindle-like shape morphol-
ogy from day 5 (Figure S3). In addition, the percentage of 
triple positive cells for CD11b, F4/80 and CD80 was below 
1.5% at all times points tested (Fig. 2c), suggesting that con-
tamination with M1-like pro-inflammatory macrophages was 
negligible. Taken these data together, a 6-day duration of 
the M-CSF + IL-4 treatment was sufficient to produce exclu-
sively M2-like macrophages from BM-MNCs.
Previous studies have reported that culture with 
M-CSF and IL-4 favored M2-like macrophage differen-
tiation/polarization of BM-MNCs in rodents [2, 5, 16, 
A
C
B D
Fig. 1  Production of M2-like macrophages by M-CSF + IL-4 treat-
ment. Mouse BM-MNCs were isolated and treated with different 
M2-like macrophage induction protocols (M-CSF plus combina-
tion of polarizing cytokines) for 7 days. Freshly isolated BM-MNCs 
and M0 macrophages (treated with M-CSF alone) were used as 
controls. Bar charts presented as mean ± SEM. a Gating strategy 
for flow cytometry procedures. Cells double positive for F4/80 and 
CD206 within the  CD11b+ population were defined as M2-like mac-
rophages by flow cytometry. Representative dot plots from samples 
of freshly isolated BM-MNCs and M-CSF + IL-4 treated BM-MNCs 
are presented. b Quantification of M2-like macrophage induction. 
Percentages of M2-like macrophages among total cultured cells were 
measured by flow cytometry at the end of the induction protocols. 
*p < 0.05 vs. all other groups; †p < 0.05 vs. BM-MNC; §p < 0.05 vs. 
M0; #p < 0.05 vs. IL-4 IL-10 TGF-β1. N = 4–7 independent samples. 
c Representative flow cytometry images for each induction protocol. 
Representative dot plots from M0; IL-10; IL-4 + IL-10; IL-4 + TGF-
β1; IL-4 + IL-10 + TGF-β1 protocols are presented. d Quantifica-
tion of M2-like macrophage yield. For each protocol, the yield after 
7  days of culture was defined as the obtained number of M2-like 
macrophages in relation to the starting number of BM-MNCs and 
expressed as a percentage. *p < 0.05 vs. all other groups; ‡p < 0.05 
vs. IL-4 + IL-10; #p < 0.05 vs. IL-4 + IL-10 + TGF-β1. N = 4–11 inde-
pendent experiments
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20, 33, 39]. However, each of these earlier reports used a 
sequential methodology, i.e., initial culture with M-CSF 
(5–7 days) followed by additional culture in the presence 
of IL-4 (24–48 h without M-CSF). We, thus, compared 
the efficacy to produce  CD11b+F4/80+CD206+ M2-like 
macrophages from BM-MNCs between this sequential 
method (5-day  M-CSF treatment followed by 24  h of 
IL-4 treatment) and our treatment (concomitant addition 
of both M-CSF and IL-4 for 6 days). As a result, it was 
demonstrated that the concomitant M-CSF + IL-4 treat-
ment led to a higher percentage of  CD11b+F4/80+CD206+ 
M2-like macrophages compared to the sequential approach 
(Fig. 2d). Following recommendations [27], cells pro-
duced using the M-CSF + IL-4 concomitant treatment 
were named M2(IL-4) macrophages.
M2(IL‑4) macrophages exhibited a reparative 
phenotype
To examine the potential ability to promote cardiac repair, 
the gene and protein expression profile of M2(IL-4) mac-
rophages was analyzed in comparison to BM-MNCs. 
M2(IL-4) macrophages showed significant upregulation of 
M2-marker genes including Arg1, Fizz1 and Ym1, as well 
as genes reported to have a potential ability of tissue heal-
ing and repair post-MI, including Igf1, Tgfb1, Spp1, and 
Ptges2 [15, 25, 29, 31, 32, 40] (Fig. 3a). Mmp9 was down-
regulated, while the gene expression of Il1ra, Vegf and 
Il-10 was not significantly different between the two cell 
types. In addition, Tnfa was downregulated in M2(IL-4) 
macrophages, highlighting the anti-inflammatory profile of 
these cells. These observations were further investigated in 
A
B C
Fig. 2  Optimization of M-CSF + IL-4 treatment. The M-CSF + IL-4 
treatment was further analyzed in terms of duration, purity and treat-
ment sequence. Bar charts presented as mean ± SEM. a Representa-
tive images for the timeline of M2-polarization by M-CSF + IL-4 
treatment. BM-MNCs were treated with M-CSF + IL-4 and ana-
lyzed for M2-like macrophage markers by flow cytometry at days 4, 
5, 6 and 7. Freshly isolated BM-MNCs (day 0) served as controls. b 
M2-like macrophage polarization timeline by M-CSF + IL-4 treat-
ment. Percentages of M2-like macrophages among total cultured cell 
numbers were calculated from flow cytometry (refer to a). *both days 
6 and 7 significant p < 0.05 vs. all days 0, 4 and 5, †p < 0.05 vs. day 
0; §p < 0.05 vs. day 4. N = 4–6 independent samples. c M1-like mac-
rophage production by M-CSF + IL-4 treatment. BM-MNCs were 
treated with M-CSF + IL-4 and analyzed for M1-like macrophage 
markers  (CD80+) by flow cytometry at days 0, 4 and 7. M1-like mac-
rophages were obtained by treatment of BM-MNCs with M-CSF, 
LPS and IFN-γ and served as positive controls. *p < 0.05. N = 4 inde-
pendent samples. d Comparison against the sequential polarization 
approach. BM-MNC were either cultured concomitantly with M-CSF 
and IL-4 for 6  days (combined) or initially with M-CSF for 5  days 
and polarized with IL-4 only for 1 further day (sequential) and ana-
lyzed for M2-like macrophage markers by flow cytometry. *p < 0.05 
vs both day 6 (sequential) and day 0; §p < 0.05 vs day. N = 4–6 inde-
pendent samples
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terms of protein secretion (Fig. 3b). Substantial increases 
in IGF-1, TGF-β1, IL-1ra and VEGF protein secre-
tion were observed in the M2(IL-4) macrophage culture 
medium when compared to BM-MNCs. These data pro-
vided evidence that M2(IL-4) macrophages have a superior 
potential of secreting anti-inflammatory and pro-reparative 
factors. To induce cardiac tissue repair post-MI in vivo, it 
is important that M2(IL-4) macrophages maintain their 
reparative phenotype in an inflammatory and ischemic 
environment. Thus, we investigated a possible re-polari-
zation of M2-like macrophages to an M1-like phenotype, 
by exposing M2(IL-4) macrophages to LPS and IFN-γ 
stimulation in vitro. As a result, it was shown that inflam-
matory stimulation did not negatively affect expression of 
tissue repair-related and M2-like marker genes, suggesting 
that M2(IL-4) macrophages could maintain their M2-like 
reparative phenotypes even after transplantation into the 
heart post-MI (Figure S4).
M2(IL‑4) macrophage transplantation showed 
augmented therapeutic effects in a mouse MI model
Although the aforementioned data suggested that M2(IL-
4) macrophages could be a suitable donor cell type for MI 
therapy, it was still to be determined whether transplanta-
tion of these cells could augment improvements in cardiac 
function in vivo. To this end, after MI induction by left 
coronary artery ligation, mice received intramyocardial 
injection of either (i) 5 × 105 M2(IL-4) macrophages pro-
duced from syngeneic mouse BM-MNCs using the above 
optimized M-CSF + IL-4 treatment, (ii) 5 × 105 freshly iso-
lated syngeneic mouse BM-MNCs or (iii) PBS control. At 
A
B
Fig. 3  Pro-reparative, anti-inflammatory phenotype of M2(IL-4) 
macrophages. Gene expression and cytokine secretion profiles of 
M2-like macrophages obtained after 6  days of M-CSF + IL-4 treat-
ment [M2(IL-4) macrophages] and freshly isolated BM-MNCs were 
compared. Bar charts presented as mean ± SEM. a Upregulation of 
M2-like macrophage markers and myocardial repair-related genes in 
M2(IL-4) macrophages. Fold change in mRNA levels were assessed 
by real-time qPCR using GAPDH as a reference gene. Expression in 
BM-MNCs was normalized to 1, which denotes no change in mRNA 
relative expression normalized to GAPDH. Data pooled from 6 to 
12 independent biological samples and three technical replicates. 
*p < 0.05. b Pro-reparative, anti-inflammatory secretome of M2(IL-4) 
macrophages. Cytokines levels were assessed by ELISA after 24 h of 
culture. Data pooled from three independent biological samples and 
two technical replicates. *p < 0.05
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28 days after cell transplantation, echocardiography dem-
onstrated that M2(IL-4) macrophage transplantation exhib-
ited an increase in left ventricular fractional shortening 
(LVFS) when compared to both BM-MNC and PBS control 
groups (29.4 ± 1.0%, 24.0 ± 0.8%, 21.2 ± 1.2%, respectively; 
Figs. 4a, b). Thus, LVFS after M2(IL-4) macrophage trans-
plantation was increased by approximately 8% compared to 
the PBS control group. BM-MNC transplantation showed 
a tendency of improvement of LVFS compared to the con-
trol but failed to achieve statistical significance. Both end-
systolic and diastolic LV dimensions were improved by 
the M2(IL-4) macrophage transplantation when compared 
to both PBS control and BM-MNC treatment. BM-MNC 
transplantation only achieved significance in reducing the 
systolic LV dimension. Furthermore, histological analysis 
revealed that M2(IL-4) macrophage transplantation reduced 
the infarct size with increased thickness of the infarcted LV 
free wall compared to both PBS control and BM-MNC 
treatment (Fig. 4c). The mortality rates were comparable 
among the groups studied. The PBS control group and the 
BM-MNC transplantation group showed a mortality rate of 
18.2% (2 out 11 mice), while the M2(IL-4) group exhibited 
a mortality rate of 21.4% (3 out of 14 mice).
M2(IL‑4) macrophages exhibited enhanced 
engraftment post‑transplantation
To investigate the factors underpinning the enhanced thera-
peutic efficacy of M2(IL-4) macrophage transplantation, 
the engraftment capacity was assessed by quantitative PCR 
for male-specific Sry gene in the LV myocardial samples. 
As the donor cells were of male origin and the recipient 
A
B
C
Fig. 4  Enhanced post-MI cardiac recovery by M2(IL-4) macrophage 
transplantation. After induction of MI by left coronary artery ligation 
in mice, 5 × 105 BM-MNCs or 5 × 105 M2(IL-4) macrophages or PBS 
alone were administered intramyocardially to the border zone sur-
rounding the infarct. Bar charts presented as mean ± SEM. a Repre-
sentative echocardiography images at day 28 after treatment. M-mode 
short axis echocardiography images highlighting changes in anterior 
wall motion in relation to treatment. b Improved cardiac function and 
reduced ventricular dimension by M2(IL-4) macrophage transplanta-
tion. LVDs (left ventricular dimension at systole), LVDd (left ven-
tricular dimension at diastole) and LVFS (left ventricular fractional 
shortening) were measured using transthoracic echocardiography (see 
a). *p < 0.05 vs. both BM-MNC and PBS groups; §p < 0.05 vs. PBS 
group. N = 9 mice in PBS and BM-MNC groups and N = 11 mice in 
M2(IL-4) group. c Increased scar thickness and reduced infarct size 
by M2(IL-4) macrophage transplantation. Hearts were collected at 
day 28 after treatment and subjected to picrosirius red staining. Rep-
resentative images of each group are presented. Thickness of infarct 
left ventricular wall and infarct size were measured using these sam-
ples. *p < 0.05 vs. both BM-MNC and PBS groups. N = 4 hearts in 
PBS and BM-MNC groups and N = 5 hearts in M2(IL-4) group
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mice were females, this method enabled a robust quantita-
tive estimation of the donor cell number existing in the heart 
[12]. The result elucidated a remarkable (> 30-fold) increase 
in donor cell engraftment for the M2(IL-4) macrophage 
transplantation (Fig. 5a). At 28 days after cell transplanta-
tion, 6.9 ± 0.8% of the total transplanted donor M2(IL-4) 
macrophages were still present in the LV in comparison to 
only 0.2 ± 0.0% for BM-MNCs. This finding was further 
validated by immunofluorescence where a sizable number 
of PKH26 pre-labelled donor cells were identified in the 
myocardium post-M2(IL-4) macrophage transplantation, 
while no PKH26-labelled cells were found in the BM-MNC 
treated hearts (Fig. 5b). In addition, transplanted M2(IL-
4) macrophages persistently expressed CD206 in  vivo 
even at 28 days post-transplantation, suggesting that the 
donor M2(IL-4) macrophages could maintain their repara-
tive M2-like phenotype despite the hazardous, inflamma-
tory environment post-MI (Fig. 5b). Of note is that donor 
cell-derived M2(IL-4) macrophages were surrounded by a 
number of PKH26-negative CD206-positive cells, i.e., host-
derived M2-like macrophages.
M2(IL‑4) macrophage transplantation improved 
myocardial tissue repair post‑MI
Various histological analyses revealed that the cardiac 
functional improvement induced by M2(IL-4) macrophage 
transplantation was underpinned by enhanced post-MI myo-
cardium repair. Picrosirius red staining demonstrated that 
M2(IL-4) macrophage therapy facilitated denser collagen 
network formation (replacement fibrosis) in the infarct area 
(Fig. 6a), compared to both BM-MNC transplantation and 
PBS control group. This would confer stability of infarcted 
ventricular wall against the risk of excessive dilatation as 
observed in Fig. 4. On the other hand, pathological intersti-
tial fibrosis in the viable myocardium of the remote and bor-
der areas was attenuated in the M2(IL-4) macrophage-treated 
hearts compared to the other groups (Fig. 6a). Although 
BM-MNC transplantation appeared to reduce interstitial 
fibrosis in the border area compared to the control group, 
this trend was not significant. Isolectin B4 staining for blood 
capillaries elucidated that there was an increased capillary 
A
B
Fig. 5  Enhanced donor cell survival after M2(IL-4) macrophage 
transplantation. Donor cell retention and localization was analyzed 
28  days post-transplantation. Bar charts presented as mean ± SEM. 
a Quantitative donor cell retention. Quantitative cell retention of 
male BM-MNCs or M2(IL-4) macrophages in the female heart (LV 
wall excluding the ventricular septum) was carried out by analyzing 
genomic DNA levels of male-specific Sry gene within the left ventric-
ular myocardium by qPCR. Sry signal was normalized for GAPDH 
expression and the corresponding number of cells was determined. 
Data presented as percentage of total transplanted cells. N = 5 hearts 
in each group; *p < 0.05. b Donor cell localization. Immunohistola-
beling for CD206 and DAPI were performed using heart samples col-
lected at day 28 after treatment. Donor cells were pre-labelled with 
PKH26 before transplantation. Representative images from the infarct 
area of the M2(IL-4) macrophage transplantation group are presented 
(lower lane). PKH26-positive donor cells were not detected in the 
BM-MNC group (upper lane). Scale bars = 50 μm
▸
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presence in the border area of M2(IL-4) macrophage-treated 
hearts compared to other groups (Fig. 6b). The same obser-
vation held true for the infarct area, while there was no dif-
ference in the remote zones where the number of capillaries 
in all groups fell within normal ranges (Figure S5). Wheat 
germ agglutinin and α-sarcomeric actinin staining showed 
that the M2(IL-4) macrophage transplantation reduced the 
size of surviving cardiomyocytes in both border and remote 
areas of the heart compared to both other groups (Fig. 6c).
M2(IL‑4) macrophage transplantation improved 
myocardial expression of reparative genes
In support of the histological findings of myocardial tissue 
repair, real-time quantitative PCR identified upregulation 
of a group of tissue repair-related factors in the M2(IL-4) 
macrophage-treated hearts. There was upregulation of Igf1, 
Arg1, Il1ra. Tgfb1, Vegf, Tnfa, Spp1, Timp1 compared to 
both BM-MNC transplantation and PBS control groups, 
while Mmp9 and Tnfa were downregulated (Fig. 7). Il-10 
gene showed no significant change in expression among all 
groups studied. Of note, the profiles of these upregulated 
reparative and inflammation-related genes in vivo were 
consistent with the findings of gene upregulation/down-
regulation of M2(IL-4) macrophages we observed in vitro 
(Fig. 3a).
M2(IL‑4) macrophage transplantation augmented 
endogenous M2‑like macrophages
In addition, we found that  CD206+ M2-like macrophages, 
which were  PKH26−, thus host-derived, were accumu-
lated primarily in the infarct area regardless of the treat-
ment (Fig. 8a). Of note, the number of  CD206+ cells was 
twice larger after M2(IL-4) macrophage transplantation 
in both infarct and peri-infarct border myocardium com-
pared to both BM-MNC transplantation and control groups 
(Fig. 8a). There was no difference between the three groups 
in the remote areas of the heart, where a small number of 
 CD206+ cells were present. We have previously shown 
that the majority of  CD206+ cells in the heart also express 
CD11b and F4/80 and have a reparative phenotype [30]. 
Therefore,  CD206+ cells found in the present experiment 
most likely were M2-like macrophages. Collectively, these 
results suggested that endogenous (host-derived) M2-like 
reparative macrophages could play a role in the paracrine 
effect induced by cell therapy as a secondary mediator arm 
[3]. Namely, transplanted M2(IL-4) macrophages would 
activate host-derived reparative macrophages, which in turn 
could provide a powerful tissue-repairing secretome possibly 
including cytokines, growth factors and exosomes, resulting 
in myocardial tissue repair.
We further investigated the mechanism of M2-like polari-
zation of host macrophages by transplantation of M2(IL-
4) macrophages. Based on the observation that Tgfb1 was 
upregulated by both M2(IL-4) macrophages in vitro (Fig. 3) 
and post-M2(IL-4) macrophage transplantation in  vivo 
(Fig. 7), we hypothesized that TGF-β1 may play a pivotal 
role in this process. To test this hypothesis, we conducted 
in vitro experiments using conditioned medium collected 
from M2(IL-4) macrophages. We found that M2(IL-4) 
macrophage conditioned medium was capable of polariz-
ing M0 macrophages to an M2-like phenotype, while anti-
body neutralization to TGF-β1 significantly reduced this 
effect (Fig. 8b), suggesting a role of TGF-β1 in M2-like 
polarization of host macrophages by transplanted M2(IL-4) 
macrophages.
Discussion
This study demonstrated that the usage of concomitant 
M-CSF and IL-4 treatment produced  CD11b+F4/80+CD206+ 
M2-like macrophages from mouse BM-MNCs more effec-
tively than other treatments studied. These generated M2(IL-
4) macrophages were found to express and secrete a more 
extensive scope of reparative and anti-inflammatory factors 
compared to BM-MNCs. We also provided robust pre-clin-
ical proof of concept data that transplantation of reparative 
macrophages, which were produced from BM-MNCs with 
M-CSF + IL-4 treatment, resulted in augmented therapeu-
tic effects, compared to BM-MNC transplantation, in a 
murine model of MI. This was associated with enhanced 
tissue repair post-MI, including augmented microvascular 
formation, reduced cardiomyocyte hypertrophy, reduced 
the inflammatory gene profile of the myocardium, thicker 
scar area formation and reduced pathological interstitial 
fibrosis, in correspondence to amplified myocardial upreg-
ulation of reparative genes. Of note, survival of reparative 
macrophages in the heart post-transplantation was increased 
as compared to BM-MNCs. In addition, it was observed 
that transplanted M2(IL-4) macrophages augmented host-
derived endogenous reparative macrophages. We, thus, 
speculate that this increase of endogenous reparative cells 
might act to further enhance cardiac repair through their 
own secretome. We identified that this unique macrophage-
to-macrophage communication occurred through TGF-β, 
at least in part. These data warrant further pre-clinical and 
clinical development of this advanced cell therapy for MI.
After 7 days of in vitro treatment with M-CSF + IL-4, 
more than 90% of BM-MNCs were converted into M2-like 
macrophages based on CD11b, F4/80 and CD206 triple pos-
itivity. In addition, this protocol was the only one, among 
all tested, which achieved increased yields from the origi-
nal BM-MNC number. This may be explained by the fact 
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that IL-4 promotes macrophage proliferation in the tissues 
beyond the homeostatic levels controlled by M-CSF [10]. 
While most of the protocols in the literature use initially 
M-CSF as a differentiation factor from BM-MNCs to M0 
(unpolarized) macrophages followed by an additional IL-4 
polarization step, we have demonstrated that the use of both 
cytokines simultaneously for the entire duration achieved a 
higher purity of CD11b, F4/80 and CD206 triple positive 
cells after only 6 days of treatment. Freshly isolated BM-
MNCs contain monocyte precursors at different maturation 
stages. This maturation process is tightly controlled in vivo 
by M-CSF [9]. It is, therefore, likely that, in vitro, the stages 
and pace of BM-MNC differentiation to macrophages in 
response to M-CSF are different. The presence of IL-4 in the 
culture medium right form the onset biases the differentia-
tion towards an M2-like phenotype of newly developed M0 
macrophages, thus shortening the total differentiation time.
Transplantation of M2-like macrophages generated 
from BM-MNCs using the M-CSF + IL-4 treatment 
resulted in marked improvements in cardiac function and 
structure post-MI, compared to BM-MNC transplantation. 
Our study suggested that two major factors underpinning 
this improved therapeutic effect were the increased quality 
and the enhanced quantity of donor cells. Firstly, the repar-
ative secretome of donor cells was enhanced in M2-like 
macrophages. In vitro studies demonstrated that M2(IL-4) 
macrophages produced from BM-MNCs exhibited expres-
sion of M2-specific markers, including Arg1, Fizz1 and 
Ym1 and indeed showed substantially increased secretion 
of VEGF, IL-1ra, IGF-1 and TGF-β1. These are known to 
contribute to myocardial repair post-MI through neovas-
cular formation, anti-inflammation, cardiac protection and 
stimulation of endogenous regeneration. In addition, Tnfa 
was downregulated in M2(IL-4) macrophages, highlight-
ing the anti-inflammatory effect of these cells. A poten-
tial concern would be that the achieved differentiation 
could not be maintained longitudinally, i.e., the M2(IL-
4) macrophages could drift towards a pro-inflammatory 
M1-like phenotype post-transplantation. However, our 
results confirmed that produced M2(IL-4) macrophages 
maintain their M2-like phenotype (in terms of expression 
of Arg1, Fizz1, Ym1, Tgfb1, Igf1 and Il1ra) even under 
a hostile, inflammatory environment in vitro as well as 
in vivo in the post-MI heart. Transplantation of M2(IL-
4) macrophages resulted in enhanced myocardial tissue 
repair post-MI, and this was correlated with upregulated 
myocardial expression of the same reparative genes as 
detected in vitro. Secondly, donor cell retention/survival 
post-transplantation was markedly improved as measured 
by both real-time PCR-based quantitative assessment and 
semi-quantitative histological investigations. While only 
less than 1% of the transplanted BM-MNCs were detect-
able, 7% of M2(IL-4) macrophages were detectable at 
28 days post-transplantation. This might be explained by 
different cellular phenotype, including differences in size 
and adhesiveness. In addition, macrophages are naturally 
found to be localized in tissues including the myocardium 
whereas BM-MNCs are immature cells and may not sur-
vive well in tissues other than bone marrow. Although it is 
highly likely that the mechanism underpinning myocardial 
repair by M2(IL-4) macrophage transplantation is the par-
acrine effect mediated by their secretome, this study does 
not completely rule out involvement of cardiomyogenic 
differentiation or fusion of donor cells. To conclude this, 
further studies using specific genetic labelling and cell fate 
tracking are needed.
Furthermore, our results provided additional mechanistic 
information on the benefits of M2(IL-4) macrophage trans-
plantation therapy. Interestingly, transplantation of donor 
M2(IL-4) macrophages augmented the number of endog-
enous, host-derived  CD206+ M2-like macrophages in the 
damaged myocardium. It is likely that the host-derived 
cardiac M2-like macrophages added a reparative ability, 
as previously reported [18]. Thus, we consider that such 
an increased endogenous M2-like macrophage number, 
together with externally added M2-like macrophages, led to 
enhanced recovery of the damaged myocardium post-MI. 
Our in vitro data demonstrated that the secretome of M2(IL-
4) macrophages was capable of polarizing M0 macrophages 
towards an M2-like phenotype and that TGF-β1 might play 
a role in this polarization process. This result is supported 
by the previous evidence that TGF-β1 can directly polar-
ize or facilitate polarization towards an M2-like phenotype 
[8, 42]. However, it is likely that not only TGF-β1 but also 
other factors contributed to the augmentation of polariza-
tion of endogenous macrophages/monocytes towards an 
M2-like phenotype. In addition, this TGF-β-mediated effect 
is likely to be only a part of the mechanism responsible for 
the enhanced myocardial repair by M2(IL-4) macrophage 
transplantation. Further studies are needed to fully under-
stand these complex mechanisms.
Fig. 6  Improved myocardial tissue repair after M2(IL-4) macrophage 
transplantation. The hearts were collected 28  days after treatment 
and analyzed for myocardial tissue repair by histological assess-
ments. Bar charts presented as mean ± SEM. *p < 0.05 vs. both PBS 
and BM-MNC groups; N = 4 hearts in PBS and BM-MNC groups 
and N = 5 hearts in M2(IL-4) group. a Picrosirius red staining for 
quantification of interstitial fibrosis. Collagen volume fraction was 
measured in the infarct, infarct border zone and remote myocardium. 
Scale bars = 20  μm. b Isolectin-B4 (IB4) staining for quantification 
of microvascular formation in the border area. The number of IB4-
positive capillaries was counted and presented as vessels/mm2. Scale 
bars = 50  μm. c Wheat germ agglutinin (WGA) and α-sarcomeric 
actinin (α-sarc) staining to measure cardiomyocyte size. The cross-
sectional area of cardiomyocytes (α-sarc+, transversely cut, central 
nuclei) in border and remote areas was measured. At least 40 cardio-
myocytes per area were assessed. Scale bars = 20 μm
◂
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Fig. 7  Upregulation of tissue 
repair-related genes in the 
myocardium after M2(IL-4) 
macrophage transplantation. 
Fold change in mRNA levels for 
myocardial repair-related factors 
were assessed in the left ventric-
ular myocardium (excluding the 
ventricular septum) collected 
at day 28 after treatment using 
real-time qPCR with GAPDH 
as a reference gene. Expres-
sion in PBS treated hearts 
was normalized to 1, which 
denotes no change in mRNA 
relative expression normalized 
to GAPDH. Data pooled from 
five independent biological 
samples in each group and three 
technical replicates. Bar charts 
presented as mean ± SEM. 
*p < 0.05 vs. both PBS and BM-
MNC groups
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Fig. 8  Augmented host-derived M2-like macrophages by M2(IL-
4) macrophage transplantation. The potential involvement of donor 
M2(IL-4) macrophages in the endogenous M2-like macrophage 
polarization process was investigated both in  vivo and in  vitro. Bar 
charts presented as mean ± SEM. a Increased M2-like macrophage 
accumulation after M2(IL-4) macrophage transplantation. Hearts 
were collected at 28  days after treatment and stained for M2-like 
 (CD206+) macrophages. The number of  CD206+ macrophages was 
calculated in the infarct, pre-infarct border, and remote myocardium. 
*p < 0.05 vs. both PBS and BM-MNC groups. N = 4 in PBS and BM-
MNC groups; N = 5 hearts in M2(IL-4) group. Scale bars = 50  μm. 
b Role of TGF-β1 in M2-like polarization induced by M2(IL-4) 
macrophages. M0 macrophages (BM-MNCs treated with M-CSF 
for 5 days) were subjected to different types of conditioned medium 
(CM) with or without neutralization antibody to TGF-β for 24  h. 
The phenotype changes were analyzed by flow cytometry. ctrl ab 
control antibody, neut ab neutralization antibody. *p < 0.05 vs. M0, 
BM-MNC CM and M2(IL-4) CM + TGF-β neutralization antibody 
groups; †p < 0.05 vs. M0 and BM-MNC CM groups; N = 4 for all 
groups except for the M2(IL-4) CM group where N = 5
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After M2(IL-4) macrophage transplantation, three types 
of reparative macrophages are potentially present in the 
heart: donor M2(IL-4) macrophage, host tissue-resident 
macrophages and host recruited monocyte-derived mac-
rophages. Our immunohistolabeling study demonstrated that 
the vast majority of  CD206+ cells in the myocardium were 
 PKH26− host-derived cells, and the number of  PKH26+ 
donor M2(IL-4) macrophages was much smaller. Consist-
ently, our Sry gene quantification showed that the presence 
of donor M2(IL-4) macrophages was minor (approximately 
30,000 cells only in a whole heart). In addition, we and 
others have reported that there is drastic reduction in the 
number of cardiac tissue-resident macrophages after MI, 
and that most macrophages in the heart after day 3 post-
MI are recruited from the circulation (monocyte-derived) 
[21, 26]. Therefore, it will be reasonable to consider that 
the majorly of M2-like macrophages observed after M2(IL-
4) macrophage transplantation are host monocyte-derived 
macrophages.
This report provides pre-clinical proof of concept data 
that support M2(IL-4) macrophage transplantation for the 
treatment of MI. However, for successful clinical translation 
of our experimental data obtained in the animal models, a 
series of focused experiments need to be completed with 
extreme caution. These include studies accounting for dif-
ferences in age, sex and co-medications, investigations using 
human cells and further optimisation of the cell-delivery 
route. It is also important to confirm the efficacy of M2(IL-
4) macrophage transplantation when it is conducted at a 
later phase post-MI in an ischemia–reperfusion model. Our 
results demonstrated that the optimal duration for M2-like 
macrophage harvesting using our M-CSF + IL-4 pre-treat-
ment protocol is 6 days. Although this time frame could be 
integrated in the current BM-MNC transplantation proto-
col for acute MI [22], a shorter pre-treatment period would 
be considered more beneficial in terms of the incurred cost 
and labor. Therefore, it will be useful to shorten the current 
6-day length of the protocol.
In conclusion, this translational study provided robust 
pre-clinical evidence for transplantation of reparative 
macrophages for the treatment of MI, which is a refined 
alternative to the current BM-MNC transplantation. The 
M-CSF + IL-4 treatment was effective in producing repara-
tive macrophages from BM-MNCs in vitro and this pre-
treatment to donor BM-MNCs improved the therapeutic 
effects of cell transplantation. Further pre-clinical and clini-
cal development of this strategy for the treatment of MI is 
warranted.
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